Tunodafil (also known as Yonkenafil) is a novel phosphodiesterase type 5 (PDE5) inhibitor, structurally and functionally related to tadalafil. While it is not yet widely approved for clinical use, research suggests that Tunodafil exhibits neuroprotective properties, including the ability to reduce cerebral infarction, neurological deficits, edema, and neuronal injury in experimental models.
As a PDE5 inhibitor, it works by increasing cyclic guanosine monophosphate (cGMP) levels, resulting in vasodilation and improved blood flow — a mechanism similar to that of approved PDE5 inhibitors used in erectile dysfunction and pulmonary arterial hypertension.
Parent: Tunodafil
Impurities in Tunodafil can occur during synthetic processing, formulation, or degradation, and they must be monitored to ensure safety, consistency, and efficacy, especially during clinical development.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Though Tunodafil is not the same as tadalafil, as a PDE5 inhibitor, it may share similar side effects. For tadalafil, common side effects include:
Tadalafil (and possibly Tunodafil) may not work effectively in:
Tadalafil — and likely Tunodafil — works by:
Avoid using tadalafil or similar PDE5 inhibitors (like Tunodafil) if you:
